Safety of anticoagulant treatment in cancer patients

Ineke Theodora Wilts; Suzanne Mariëlla Bleker; Nick van Es; Harry Roger Büller; Marcello Di Nisio; Pieter Willem Kamphuisen

doi:https://doi.org/10.1517/14740338.2015.1052739

Safety of anticoagulant treatment in cancer patients

Ineke Theodora Wilts, Suzanne Mariëlla Bleker, Nick van Es, Harry Roger Büller, Marcello Di Nisio, Pieter Willem Kamphuisen

Research output: Contribution to journal › Review article › Academic › peer-review

10 Citations (Scopus)

Abstract

Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at increased risk of bleeding. This makes treatment of venous thromboembolisms (VTE) in cancer patients challenging. In this review, we will focus on the safety of anticoagulant treatment of VTE in cancer patients. We will discuss the absolute and relative bleeding risks associated with the various types of anticoagulants, specifically focusing on low-molecular-weight heparins (LMWH), vitamin K antagonist (VKA) and the new oral anticoagulants (NOACs). Monotherapy with LMWH is recommended for treatment of acute VTE in cancer patients. The bleeding risk associated with LMWH is comparable to VKAs, but LMWH are more effective in preventing recurrent VTE. More evidence on the efficacy and safety of NOACs in cancer patients is needed

Original language	English
Pages (from-to)	1227-1236
Journal	Expert opinion on drug safety
Volume	14
Issue number	8
DOIs	https://doi.org/10.1517/14740338.2015.1052739
Publication status	Published - 2015

Access to Document

https://doi.org/10.1517/14740338.2015.1052739

Cite this

@article{d4703fb6eb154900abaccc677e8d6024,

title = "Safety of anticoagulant treatment in cancer patients",

abstract = "Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at increased risk of bleeding. This makes treatment of venous thromboembolisms (VTE) in cancer patients challenging. In this review, we will focus on the safety of anticoagulant treatment of VTE in cancer patients. We will discuss the absolute and relative bleeding risks associated with the various types of anticoagulants, specifically focusing on low-molecular-weight heparins (LMWH), vitamin K antagonist (VKA) and the new oral anticoagulants (NOACs). Monotherapy with LMWH is recommended for treatment of acute VTE in cancer patients. The bleeding risk associated with LMWH is comparable to VKAs, but LMWH are more effective in preventing recurrent VTE. More evidence on the efficacy and safety of NOACs in cancer patients is needed",

author = "Wilts, {Ineke Theodora} and Bleker, {Suzanne Mari{\"e}lla} and {van Es}, Nick and B{\"u}ller, {Harry Roger} and {Di Nisio}, Marcello and Kamphuisen, {Pieter Willem}",

year = "2015",

doi = "https://doi.org/10.1517/14740338.2015.1052739",

language = "English",

volume = "14",

pages = "1227--1236",

journal = "Expert opinion on drug safety",

issn = "1474-0338",

publisher = "Informa Healthcare",

number = "8",

}

TY - JOUR

T1 - Safety of anticoagulant treatment in cancer patients

AU - Wilts, Ineke Theodora

AU - Bleker, Suzanne Mariëlla

AU - van Es, Nick

AU - Büller, Harry Roger

AU - Di Nisio, Marcello

AU - Kamphuisen, Pieter Willem

PY - 2015

Y1 - 2015

N2 - Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at increased risk of bleeding. This makes treatment of venous thromboembolisms (VTE) in cancer patients challenging. In this review, we will focus on the safety of anticoagulant treatment of VTE in cancer patients. We will discuss the absolute and relative bleeding risks associated with the various types of anticoagulants, specifically focusing on low-molecular-weight heparins (LMWH), vitamin K antagonist (VKA) and the new oral anticoagulants (NOACs). Monotherapy with LMWH is recommended for treatment of acute VTE in cancer patients. The bleeding risk associated with LMWH is comparable to VKAs, but LMWH are more effective in preventing recurrent VTE. More evidence on the efficacy and safety of NOACs in cancer patients is needed

AB - Patients with cancer are at increased risk of (recurrent) venous thromboembolism. They are also at increased risk of bleeding. This makes treatment of venous thromboembolisms (VTE) in cancer patients challenging. In this review, we will focus on the safety of anticoagulant treatment of VTE in cancer patients. We will discuss the absolute and relative bleeding risks associated with the various types of anticoagulants, specifically focusing on low-molecular-weight heparins (LMWH), vitamin K antagonist (VKA) and the new oral anticoagulants (NOACs). Monotherapy with LMWH is recommended for treatment of acute VTE in cancer patients. The bleeding risk associated with LMWH is comparable to VKAs, but LMWH are more effective in preventing recurrent VTE. More evidence on the efficacy and safety of NOACs in cancer patients is needed

U2 - https://doi.org/10.1517/14740338.2015.1052739

DO - https://doi.org/10.1517/14740338.2015.1052739

M3 - Review article

C2 - 26059964

SN - 1474-0338

VL - 14

SP - 1227

EP - 1236

JO - Expert opinion on drug safety

JF - Expert opinion on drug safety

IS - 8

ER -